Roche and Synta Pharmaceuticals entered an agreement potentially worth $1.025 billion to discover, develop, and commercialize small molecule anti-inflammatories. Roche will pay Synta $25 million upfront, which includes $9 million in research funding ...
Read more...
Helping adolescents with arthritis develop the skills and secure resources to assure that their health care needs are met as they transition to adulthood is an important issue in the U.S. In general, the frequency of which young people with special ...
Read more...
Ann Arbor-based Velcura Therapeutics Inc. said Wednesday that it had completed its second successful Investigational New Drug application to the United States Food and Drug Administration for its lead compound, VEL-0230. The November 2008 IND filing ...
Read more...
CHAPEL HILL, NC—Attorney Sheila Mikhail is once again showing that raising venture money is not the only way to get a promising start up going, even in the money-hungry field of biotech. Not only that, sometimes, all that’s necessary to improve ...
Read more...
VIENNA, Va. , Jan. 7 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE Alternext US : CVM ) announced today the initiation of a definitive study of its new rheumatoid arthritis treatment vaccine (CEL-2000) to determine the long-lasting beneficial ...
Read more...
ANN ARBOR, Mich. January 07, 2009 /PRNewswire/ -- Velcura Therapeutics Inc., a clinical-phase biotechnology company developing therapies for bone disease, has completed its second successful Investigational New Drug application (IND) to the U.S. Food ...
Read more...
CHICAGO, Jan 7 (Reuters) - A drug used to suppress the immune system in cancer and rheumatoid arthritis has helped extend the life of a Minnesota boy struggling with a rare and deadly form of the genetic disorder Pompe disease. A team of researchers ...
Read more...